PRKAA1 and cancer: For example, simultaneous activation of parallel pathways such as MAPK/ERK by AdipoRon has been reported in various cancer models, suggesting a potential for pathway cross-talk that may influence or obscure AMPK signaling outcomes in vivo (22, 45).